183 related articles for article (PubMed ID: 29765120)
1. Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Ge P; Wang L; Lu M; Mao L; Li W; Wen R; Lin J; Wang J; Chen J
Sci Rep; 2018 May; 8(1):7543. PubMed ID: 29765120
[TBL] [Abstract][Full Text] [Related]
2. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
[TBL] [Abstract][Full Text] [Related]
4. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
[TBL] [Abstract][Full Text] [Related]
5. Prognostic variations between 'primary' and 'progressive' muscle-invasive bladder cancer following radical cystectomy: a novel propensity score-based multicenter cohort study.
Lai S; Liu J; Lai CH; Seery S; Hu H; Wang M; Hu H; Xu T
Int J Surg; 2024 Jan; 110(1):270-279. PubMed ID: 37738002
[TBL] [Abstract][Full Text] [Related]
6. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
[TBL] [Abstract][Full Text] [Related]
7. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
8. Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
Fonteyne V; Ost P; Bellmunt J; Droz JP; Mongiat-Artus P; Inman B; Paillaud E; Saad F; Ploussard G
Eur Urol; 2018 Jan; 73(1):40-50. PubMed ID: 28478043
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study.
Nouhaud FX; Chakroun M; Lenormand C; Ouzaid I; Peyronnet B; Gryn A; Prudhomme T; Grafeille V; Soulié M; Roumiguié M; Verhoest G; Xylinas E; Bouzouita A; Chebil M; Pfister C
Urol Oncol; 2021 Mar; 39(3):195.e1-195.e6. PubMed ID: 33214030
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
[TBL] [Abstract][Full Text] [Related]
11. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
12. Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment.
Møller CT; Fosså SD; Tafjord G; Babigumira R; Berge V; Andreassen BK
Scand J Urol; 2022 Jun; 56(3):214-220. PubMed ID: 35506475
[TBL] [Abstract][Full Text] [Related]
13. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.
van den Bosch S; Alfred Witjes J
Eur Urol; 2011 Sep; 60(3):493-500. PubMed ID: 21664041
[TBL] [Abstract][Full Text] [Related]
14. B7‑H3 promotes malignant progression of muscle‑invasive bladder cancer.
Xu ZL; Zhang Y; Wang L; Li F; Man HW; Li PF; Shan BE
Oncol Rep; 2018 Nov; 40(5):2722-2733. PubMed ID: 30132557
[TBL] [Abstract][Full Text] [Related]
15. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.
Kim KH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Urol Oncol; 2013 Nov; 31(8):1643-9. PubMed ID: 22591745
[TBL] [Abstract][Full Text] [Related]
16. Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.
Mori K; Yanagisawa T; Katayama S; Laukhtina E; Pradere B; Mostafaei H; Quhal F; Rajwa P; Moschini M; Soria F; D'andrea D; Abufaraj M; Albisinni S; Krajewski W; Fukuokaya W; Miki J; Kimura T; Egawa S; Teoh JY; Shariat SF;
World J Urol; 2023 Apr; 41(4):909-919. PubMed ID: 35963957
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer.
Ebbing J; Heckmann RC; Collins JW; Miller K; Erber B; Friedersdorff F; Fuller TF; Busch J; Seifert HH; Ardelt P; Wetterauer C; Hosseini A; Jentzmik F; Kempkensteffen C
Sci Rep; 2018 May; 8(1):8360. PubMed ID: 29849039
[TBL] [Abstract][Full Text] [Related]
18. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
[TBL] [Abstract][Full Text] [Related]
19. The natural history of secondary muscle-invasive bladder cancer.
Hidas G; Pode D; Shapiro A; Katz R; Appelbaum L; Pizov G; Zorn KC; Landau EH; Duvdevani M; Gofrit ON
BMC Urol; 2013 May; 13():23. PubMed ID: 23656972
[TBL] [Abstract][Full Text] [Related]
20. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
